Clinical trial · Observational
Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
NCT06647602CI-TRIAL-00102887THRIVEnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Differentiated Thyroid Cancer | Thyroid Gland Neoplasm | PROBABILISTIC | 0.70 |
| Levothyroxine | — | UNRESOLVED | — |
| Liothyronine | — | UNRESOLVED | — |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
| Thyroid Hormones | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytomel (liothyronine) | Drug | — | UNRESOLVED |
| Euthyrox (levothyroxine) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- TH-combination cohort
- description
- L-T4+L-T3 combination according to local protocol.
- interventionNames
- Drug: Cytomel (liothyronine)
- label
- Levothyroxine cohort
- description
- L-T4 monotherapy according to local protocol.
- interventionNames
- Drug: Euthyrox (levothyroxine)
Primary outcomes (1)
- measure
- TSH after two weeks of TH substitution
- timeFrame
- Before and after 2 weeks of TH-substitution
- description
- The percentage of patients reaching target TSH (\<0.5 mU/L) after two weeks of L-T3+L-T4 substitution compared to patients with L-T4-substitution.
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma) * Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician). * Prepared for RAI-therapy with TH-withdrawal * Patients must be fit to adhere to the study protocol * Patients must be able to read and understand the Dutch language Exclusion Criteria: * Pregnancy * Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable. * Conditions or drugs interfering with thyroid hormone uptake: * Patients with a history of atrophic gastritis * Patients using proton-pomp inhibitors
References
Publications (0)
Data not yet available
No reference posted for this study.